Pancreatic, colorectal, and liver cancers are notoriously quiet killers because they rarely show symptoms in their early stages, and non-invasive detection tools have historically been lacking.
To solve this clinical hurdle, the EG BioMed research team—in close collaboration with Taipei Medical University and its hospital network (TMUH, Wanfang, Shuang Ho)—has developed a high-performance liquid biopsy technology: A single blood test designed to detect multiple early-stage gastrointestinal cancers simultaneously.
Core Highlights: Why is this a game-changer?
Elite Sensitivity for Early Cancers: The test successfully captured silent, early-stage (Stage I/II) tumors, achieving a success rate of 93.8% for pancreatic cancer, 88.9% for colorectal cancer, and 87.5% for liver cancer.
100% Detection for Advanced Stages: For Stage III/IV patients, the detection rate reached a definitive 100%.
Highly Accurate, Minimal False Alarms: With a 95% overall specificity, the test drastically minimizes the chances of false positives, saving healthy individuals from unnecessary panic.
Proven Worldwide: The biomarkers were validated across both Taiwanese and U.S. clinical trials, showing exceptional accuracy regardless of the patient’s ethnic background.
How It Works
When tumors start growing, they shed tiny fragments of DNA into our bloodstream, leaving behind unique chemical “fingerprints” (DNA methylation profiles). EG BioMed’s assay acts as a high-tech radar, scanning a single tube of blood to spot two key tumor indicators: TMEM240 and ZFP30/ZNF781.
Backed by YD Bio, EG BioMed is aggressively expanding its liquid biopsy platform globally, turning cancer detection into a simple, scalable, and non-invasive routine to save lives through timely intervention.